Format

Send to

Choose Destination
Haematologica. 2019 May 17. pii: haematol.2018.212266. doi: 10.3324/haematol.2018.212266. [Epub ahead of print]

Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model.

Author information

1
Apoptosis Research Center, National University of Ireland, Galway, Ireland.
2
Maine Medical Center Research Institute, Scarborough, ME, USA.
3
Department of Chemistry and of Medical Microbiology and Immunology, University of Alberta, Canada.
4
Apoptosis Research Center, National University of Ireland, Galway, Ireland; michael.odwyer@nuigalway.ie.

Abstract

Aberrant glycosylation resulting from altered expression of sialyltransferases, such as ST3 beta-galactoside alpha2-3-sialyltransferase 6, plays an important role in disease progression in multiple myeloma. Hypersialylation can lead to increased immune evasion, drug resistance, tumor invasiveness, and disseminated disease. In this study, we explore the in vitro and in vivo effects of global sialyltransferase inhibition on myeloma cells using the pan-sialyltransferase inhibitor 3Fax-Neu5Ac delivered as a peracetylated methyl ester pro-drug. Specifically, we show in vivo that 3Fax-Neu5Ac improves survival by enhancing bortezomib sensitivity in an aggressive mouse model of multiple myeloma. However, 3Fax-Neu5Ac treatment of multiple myeloma cells in vitro did not reverse bortezomib resistance conferred by bone marrow stromal cells. Instead, 3Fax-Neu5Ac significantly reduced interactions of myeloma cells with E-selectin, MADCAM1 and VCAM1, suggesting that reduced sialylation impairs extravasation and retention of myeloma cells in the bone marrow. Finally, we showed that 3Fax-Neu5Ac alters the post-translational modification of the α4 integrin, which may explain the reduced affinity of α4β1/α4β7 integrins for their counter-receptors. We propose that inhibiting sialylation may represent a valuable strategy to restrict myeloma cells from entering the protective bone marrow microenvironment, a niche in which they are normally protected from chemotherapeutic agents such as bortezomib. Thus, our work demonstrates that targeting sialylation to increase the ratio of circulating to bone marrow-resident multiple myeloma cells represents a new avenue that could increase the efficacy of other anti-myeloma therapies and holds great promise for future clinical applications.

KEYWORDS:

Bone Marrow Microenvironment; E-Selectin; MADCAM1; Multiple Myeloma; sialyltransferase inhibitor

PMID:
31101754
DOI:
10.3324/haematol.2018.212266
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center